Chronic Heart Failure Flashcards
heart “failure”
heart not able to supply enough oxygen-rich blood
from impaired ventricle ability to fill or eject blood
causes of HF
MI
long-standing hypertension
general symptoms of HF
SOB/Dypsnea
cough
fatigue/weakness
reduced exercise capacity
lab/biomarkers of HF
inc BNP (norm is <100)
inc NT-proBNP (normal is <300)
shows cardiac vs non-cardiac causes of dyspnea
left-sided signs and symptoms
orthopnea: SOB lying flat
paroxysmal nocturnal dyspnea (PND): nocturnal cough and SOB
bibasilar rales: crackling lung sounds heart on lung exam
S3 gallop: abnormal heart sound
hypoperfusion (renal impairment, cool extremities)
right-sided signs and symptoms
peripheral edema
ascites: abdominal fluid
jugular venous distention
hepatojugular reflux
hepatomegaly: enlarged liver from fluid congestion
CO
blood pumped by heart in 1 min
HR x SV = CO
stroke volume
volume of blood ejected from left ventricle in 1 heartbeat
compensatory mechanisms
neurohormonal pathways to inc blood volume or force/speed of contractions
leads to cardiac remodeling
RAAS
SNS
vasopressin
natriuretic peptides that balance become deficient
Angiotensin II
vasoconstrictor
aldosterone
sodium and water retention
vasopressin
vasoconstriction and water retention
SNS activation = NE
inc HR
inc contractility (positive inotrope)
vasoconstriction
lifestyle
monitor/document body weight daily
notify provider if weight inc 2-4 pounds in 1 day or 3-5 pounds in 1 week or if symptoms worsen
restrict sodium <1500 mg/day in stage A and B
ejection fraction
<=40%
HFrEF
systolic dysfunction
impaired ability to eject blood during systole
ACC/AHA
american college of cardiology and american heart association
NYHA
new york heart association
ACC/AHA Stage B
pre-HF
no signs/symptoms of HF but with structural heart disease, abnorm cardiac function, inc biomarkers
ACC/AHA Stage C
structural and/or function cardiac abnormality with prior/current symptoms
NYHA Class II
in ACC/AHA Stage C
ordinary physical activity results in HF symptoms
NYHA Class IV
in ACC/AHA Stage C or D
symptoms of HF with all physical activity or symptoms of HF at rest
ACC/AHA Stage D
advanced with severe symptoms, symptoms at rest
natural products
omega-3 fatty acids/fish oils
hawthorn and coenzyme Q10
Beta blockers in drug treatment
dec SNS = dec HR, dec contractility, negative inotrope
dec mortality
ACEI/ARBs/ARA in drug treatment
dec RAAS = dec vasoconstriction/afterload; dec fluid retnetion/preload
dec mortality
loop diuretics in drug treatment
dec fluid retention/preload
dec symptoms
no decrease in mortality
digoxin in drug treatment
inc CO
dec hospitalizations
no decrease in mortality
sacubitril in drug treatment
inc natriuretic peptides = inc vasodilation/diuresis
dec mortality
initial meds rec for all w/o CI
ARNI/ACEI/ARB: ARNI preferred bc more morbidity/mortality dec
beta-blockers
control HR/reduce arrhythmia risk
loop diuretics: reduce blood volume = dec edema/congestion
secondary add-on medications
ARA: dec morbidity/mortality; more diueresis; dec symptoms; inc EF; meed eGFR, SCr, K criteria
SGLT2i: dec morbidity/mortality; meet eGFR criteria
hydralazine and nitrates (BiDil): dec morbidity/mortality in black patients/patients who cannot tolerate ACEi/ARB
Ivabradine (Corlanor): dec hospitalization; normal sinus rhythm and HR >=70 on max BB
addition medications
digoxin: small inc CO; improve symptoms/dec hospitalization (not mortality)
vericiguat, soluble guanylate cyclase stimulator: dec hospitalzation and CV death after hospitalization / need for IV diuretics; not in guidelines
Entresto MOA
neprilysin inhibitor (sacubitril) = stops degradation of vasodilatory peptides
dec HF hospitalizations/cardiovascular death
first line
use in place of ACEI/ARB
Entresto BBW
injury and death to developing fetus
d/c as soon as pregnancy found
Entresto CI
do not use w/i 36 hrs of ACEi
do not use with angioedema history
Entresto warnings
angioedema
hyperkalemia
hypotension
renal impairment
bilateral renal artery stenosis (avoid)
Entresto side effects
cough
hyerkalemia
inc SCr
hypotension
Entresto monitoring
BP
K
renal function
s/sx of HF
Entresto notes
do not use with ACEi/ARB
ACEI MOA
block angiotensin I to II = dec vasoconstriction and aldosterone secretion
ARBs MOA
block Ang II binding to AT1 receptor
captopril dosing
TID